Medications

Indiana University Researchers to Study Use of Tezampanel for Opioid Withdrawal
The Indiana University School of Medicine has received a $12.3 million grant from the National Institute on Drug Abuse for a two-stage research project to study the use of tezampanel to treat opioid withdrawal syndrome, as well as other addictions and mental illnesses.
Overdose Prevention Group, Emergent BioSolutions, MLB Clubs Join Forces on Campaign
Not-for-profit organization Mothers Against Prescription Drug Abuse, life sciences firm Emergent BioSolutions, and three Major League Baseball clubs team up for Overdose Awareness Day initiative.
Less Than a Quarter of Americans Accurately Identify Opioids in Study
More than three-quarters of survey respondents said they think they know when they are prescribed an opioid, but just 22% could successfully identify seven common prescribed opioids, with many also frequently misidentifying other medications as containing opioids.
FDA Makes Series of Recommendations on Naloxone
In a recently published communication, FDA recommended that providers discuss the availability of naloxone with patients and consider prescribing it to those deemed at increased risk of overdose.
Telemedicine Program Seeks to Remove All Barriers to OUD Medication
Workit Health's telemedicine program is allowing patients with substance use disorders to dip a toe into the waters of early recovery, its co-founder said at the Rx Drug Abuse & Heroin Summit.
Report: Researchers Studying Naltrexone for Treatment of COVID-19 Symptoms
Researchers from Beaumont Health System in Michigan are studying whether naltrexone can be used to help manage symptoms of individuals with a COVID-19 infection, according to a report from Detroit’s NPR affiliate.
Buprenorphine Analog Shows Potential for Treating Cocaine Addiction in Study
In a study of mice, a buprenorphine analog was found to be more effective at activating receptors that prevent cocaine relapse without increasing addiction potential, according to a Science Magazine report.
Lofexidine Demonstrates Efficacy During Early Opioid Withdrawal
SAN DIEGO—The opioid withdrawal drug lofexidine demonstrated statistically significant efficacy across a half-dozen patient- and clinician-reported outcomes during the first 7 days after immediate opioid cessation, according to study presented at…
Managing Patients With Opioid Use Disorder and Chronic Pain
SAN DIEGO—Mental health clinicians will likely be taking on many more patients with opioid use disorder, as 40% of primary care providers will not accept any new patients who take opioids, an expert said at Psych Congress 2019.
Panelists: MAT is Not a Harm Reduction Strategy; Syringe Exchanges Working as Intended
There was universal agreement among panelists during a Sunday morning session at the National Conference on Addiction Disorders East about the benefits of harm reduction strategies. They prevent overdose deaths and the spread of infectious diseases…
Back to Top